Skip to main content
. Author manuscript; available in PMC: 2014 Jun 30.
Published in final edited form as: Eur J Immunol. 2012 Oct 16;42(12):3291–3301. doi: 10.1002/eji.201242689

Figure 4. Transgenic BAFF can support MSP119-specific ASCs survival during malaria.

Figure 4

(A) A representation of the protocol used to show that soluble BAFF in transgenic mice improves MSP119-specific ASC survival during malaria is shown. (B) Bar chart shows a comparison of the numbers of IgG MSP119-specific ASCs/spleen in BAFF-Tg and WT mice during P. yoelii YM-malaria or following MSP119-boost. (C) The percentage parasitemia over 150 days in naive WT and BAFF-Tg mice infected with P. yoelii YM are shown. (B, C) Data are shown as mean ± SEM of 5–6 independently processed mice/group and are representative of 2–3 independent assays which gave similar results. Significance was analyzed using the non-parametric Mann-Whitney U test on pooled data from replicate experiments. *P<0.0403; **P<0.0014; ***P<0.0007; ****P=<.0.0004.